In a report released on October 22, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

The allergy treatment market is set to experience robust growth, with an estimated valuation of US$ 20.20 billion in 2022 and ...

Infertility Drugs MarketThe global infertility drugs market is set for significant growth over the next decade, with the ...

On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Shares of Incyte have risen 3.9% in the year-to-date period against the industry’s decline of 1.8%. Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Check the time stamp on this data. Updated AI-Generated Signals for Novartis Ag (NVS) available here: NVS.